Rondy Marc, Tamboura Mamadou, Sidikou Fati, Yameogo Issaka, Dinanibe Kambire, Sawadogo Guetwende, Kambire Chantal, Mainassara Halima, Mahamane Ali Elhaj, Bienvenu Baruani, Moussa Haladou, Ouedraogo Rasmata, Fernandez Katya, Taha Muhamed-Kheir, Ronveaux Olivier
Family, Gender and Life Course Department, Comprehensive Family Immunization Unit, Pan American Health Organization, Washington, DC 20037, USA.
Centre Hospitalier Universitaire Pédiatrique-Charles De Gaulle, Ouagadougou 01 BP 1198, Burkina Faso.
Microorganisms. 2021 Apr 14;9(4):832. doi: 10.3390/microorganisms9040832.
New lateral flow tests for the diagnosis of (Nm) (serogroups A, C, W, X, and Y), MeningoSpeed, and (Sp), PneumoSpeed, developed to support rapid outbreak detection in Africa, have shown good performance under laboratory conditions. We conducted an independent evaluation of both tests under field conditions in Burkina Faso and Niger, in 2018-2019. The tests were performed in the cerebrospinal fluid of suspected meningitis cases from health centers in alert districts and compared to reverse transcription polymerase chain reaction tests performed at national reference laboratories (NRLs). Health staff were interviewed about feasibility. A total of 327 cases were tested at the NRLs, with 26% confirmed Nm (NmC 63% and NmX 37%) and 8% Sp. Sensitivity and specificity were, respectively, 95% (95% CI: 89-99) and 90% (95% CI: 86-94) for Nm and 92% (95% CI: 75-99) and 99% (95% CI: 97-100) for Sp. Positive and negative predictive values were, respectively, 77% (95% CI: 68-85) and 98% (95% CI: 95-100) for Nm and 86% (95% CI: 67-96) and 99% (95% CI: 98-100) for Sp. Concordance showed 82% agreement for Nm and 97% for Sp. Interviewed staff evaluated the tests as easy to use and to interpret and were confident in their readings. Results suggest overall good performance of both tests and potential usefulness in meningitis outbreak detection.
为支持非洲地区快速疫情检测而研发的用于诊断脑膜炎奈瑟菌(Nm,血清群A、C、W、X和Y)的新型侧向流动检测试剂MeningoSpeed以及用于诊断肺炎链球菌(Sp)的PneumoSpeed,在实验室条件下已显示出良好性能。2018 - 2019年,我们在布基纳法索和尼日尔的现场条件下对这两种检测试剂进行了独立评估。检测在警戒区卫生中心疑似脑膜炎病例的脑脊液中进行,并与国家参考实验室(NRLs)进行的逆转录聚合酶链反应检测结果相比较。就可行性问题对卫生工作人员进行了访谈。国家参考实验室共检测了327例病例,其中26%确诊为脑膜炎奈瑟菌(NmC占63%,NmX占37%),8%为肺炎链球菌。脑膜炎奈瑟菌检测的敏感性和特异性分别为95%(95%置信区间:89 - 99)和90%(95%置信区间:86 - 94),肺炎链球菌检测的敏感性和特异性分别为92%(95%置信区间:75 - 99)和99%(95%置信区间:97 - 100)。脑膜炎奈瑟菌检测的阳性预测值和阴性预测值分别为77%(95%置信区间:68 - 85)和98%(95%置信区间:95 - 100),肺炎链球菌检测的阳性预测值和阴性预测值分别为86%(95%置信区间:67 - 96)和99%(95%置信区间:98 - 100)。一致性显示,脑膜炎奈瑟菌检测的一致性为82%,肺炎链球菌检测的一致性为97%。接受访谈的工作人员评价这些检测试剂易于使用和解读,并对检测结果有信心。结果表明这两种检测试剂总体性能良好,在脑膜炎疫情检测中具有潜在用途。